ZCA
SGYP

Zeke Capital Advisors’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Zeke Capital Advisors’s Portfolio SGYP Stock Details SGYP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-21,700
Closed -$38K – 787
2018
Q2 		$38K Buy
21,700
+5,321
+32% +$9.2K ﹤0.01% 627
2018
Q1 		$30K Hold
16,379
– – ﹤0.01% 645
2017
Q4 		$37K Buy
+16,379
New +$40.7K ﹤0.01% 559

Other funds holding SGYP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Zeke Capital Advisors's SGYP Position: Q3 2018 in Review

Zeke Capital Advisors sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q3 2018, closing a stake of 21,700 shares — an estimated $38K sold.

Zeke Capital Advisors first reported a position in SGYP in Q4 2017 and held it in 3 quarters. The position peaked at $38K in Q2 2018. 133 funds tracked by Wall St. Rank hold SGYP as of Q3 2018.

  • Zeke Capital Advisors reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q3 2018 after selling out during the quarter.
  • Zeke Capital Advisors sold 21,700 Synergy Pharmaceuticals, Inc Common Stock shares in Q3 2018, an estimated $38K.
  • Zeke Capital Advisors first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q4 2017 and held it in 3 quarters.
  • Zeke Capital Advisors's Synergy Pharmaceuticals, Inc Common Stock position peaked at $38K in Q2 2018.
  • 133 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q3 2018.

Based on Zeke Capital Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.